Inactive Instrument

Reunion Neuroscience

FTRP

CA76134G1037

Reunion Neuroscience Kept at Speculative Buy at Stifel GMP After FQ2 Report; Price Target Cut 63% to C$5.00

Published on 11/15/2022 at 11:33 am EST - Modified on 11/15/2022 at 11:34 am EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Reunion Neuroscience

Sep. 30	Reunion Neuroscience, Inc. Announces First Patient Dosed in REKINDLE Phase 2 Clinical Trial of RE104 for the Treatment of Adjustment Disorder in Cancer and Other Medical Illness	CI
Sep. 16	Reunion Neuroscience Inc. announced that it has received $133 million in funding from a group of investors	CI
Sep. 16	Reunion Neuroscience, Inc. Plans to Advance RE104 into Clinical Development for the Treatment of Generalized Anxiety Disorder	CI
Aug. 18	Reunion Neuroscience, Inc. Announces Positive Topline Results from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression	CI
Jul. 22	Reunion Neuroscience Announces Publication of RE104 Phase 1 Data in The Journal of Clinical Psychopharmacology	CI
May. 19	Reunion Neuroscience, Inc. Announces Last Patient Dosed in RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression	CI
24-10-09	Reunion Neuroscience Partners with Seleni Institute on Effective Diagnosis and Treatment of Maternal Mental Health Disorders	CI
24-07-23	Reunion Neuroscience Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression	CI
24-05-20	Reunion Neuroscience Announces Publication of Results from Early Preclinical Studies Demonstrating the Potential of Re104 for Development in Depressive Disorders	CI
24-05-02	Reunion Neuroscience Inc. Announces Advancing RE104, Its Proprietary, Clinical-Stage Serotonergic Psychedelic Drug Candidate to Provide Benefits to Patients with Underserved Mental Health Disorders	CI
Sep. 16	Reunion Neuroscience Inc. disclosed investors participating in the transaction	CI
23-09-18	Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate A Phase 2 Study of Re104 for the Treatment of Postpartum Depression	CI
23-08-01	Reunion Neuroscience Brief: Reunion and MPM BioImpact Complete Plan of Arrangement Effective Today, whereby MPM Acquired Reunion in an all-cash transaction valued at Near US$13.1 million	MT
23-08-01	Reunion Neuroscience Inc.(NasdaqGS:REUN) dropped from NASDAQ Composite Index	CI
23-07-31	MPM Asset Management, L.L.C. acquired Reunion Neuroscience Inc. in a going private transaction.	CI
23-07-14	Reunion Neuroscience Gets Ontario Court's Final Approval for Acquisition by MPM BioImpact	MT
23-07-14	Reunion Neuroscience Brief: Adds In "Assuming Remaining Conditions Precedent Are Satisfied Or Waived", Anticipates Closing of Arrangement Will Occur On Or About July 21, 2023	MT
23-07-14	Reunion Neuroscience Brief: Says Obtained Final Court Order for Proposed Plan of Arrangement Whereby Affiliates of MPM BioImpact Will Buy REUN In An All-cash Deal Valued at Near US$13.1 Million	MT
23-07-13	Reunion Neuroscience Brief: Arrangement remains subject to receipt of a final order of the Ontario Superior Court of Justice (Commercial List); Expected to be completed on or around July 21, 2023	MT
23-07-13	Reunion Neuroscience Brief: Shareholders Approve Proposed Plan of Arrangement Whereby Affiliates of MPM BioImpact Will Buy REUN In An All-cash Tansaction Valued at Near US$13.1 Million	MT
23-06-29	Reunion Reports Q4 Results; Shareholders to Get US$1.12 Cash Per Share From Arrangement Agreement with MPM BioImpact	MT
23-06-29	Reunion Neuroscience Brief: Adds It Presented "Encouraging" Phase 1 Final Analysis at American Society of Clinical Psychopharmacology Annual Meeting	MT
23-06-29	Reunion Neuroscience Brief: Common Holders to Receive Consideration of US$1.12 Per Share in Cash from Arrangement Agreement with MPM BioImpact; Special Shareholder Meeting Scheduled July 12	MT
23-06-29	Reunion Neuroscience Brief: Says incurred a net loss from continuing operations of $6.5 million or $0.56 per share and $38.1 million or $3.28 per share for the three and 12 month periods ended March 31, 2023	MT
23-06-29	Reunion Neuroscience Brief: Says Rcognized a net loss from discontinued operations of $10.4 million for the 12 month period ended March 31, 2023; Adds No such loss was incurred during the three month period ended March	MT

Reunion Neuroscience Inc. is engaged in the psychedelic drug development company that provides therapeutic solutions for mental health conditions by developing serotonin receptor agonist compounds. The Company is developing the advancement of synthetic molecules targeting serotonin 5HT2A receptors. The Company's products include RE104 and RE200. The Company's lead asset, RE-104, which is a psychedelic drug being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant with durable efficacy. The RE104 as a potentially fast-acting treatment for the key indications of postpartum and treatment resistant depression. The Company is developing the RE200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psych activity for potential use in more chronic treatment paradigms and indications. The Company is focused on the research and development of its RE200 molecule group.

Employees

Sector

Pharmaceuticals

More about the company